IP Library Granted Patent US 8,252,331
Granted Patent B2
US 8,252,331 · App. 11/287,882 · Granted Aug 28, 2012

Osmotic device containing amantadine and an osmotic salt

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,252,331
App. No.
11/287,882
Granted
Aug 28, 2012
Kind
B2
Abstract

The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is modified from a first order release profile to a zero order, pseudo-zero order or sigmoidal release profile by increasing the amount of the osmotic salt in the core of the device. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt.

Claims (144)

1. An osmotic device having a unitary core surrounded by a semipermeable membrane having at least one passageway there through, wherein:

a) the unitary core comprises a mixture of amantadine salt, osmotic salt, and at least one other pharmaceutically acceptable excipient, wherein the amantadine salt is amantadine hydrochloride and the osmotic salt is sodium chloride, and the weight ratio of amantadine salt to osmotic salt ranges from 2:1 to 30:1;

b) the osmotic salt is not coated with a release rate controlling coating;

c) the permeability of the semipermeable membrane is adapted to cooperate with the osmotic salt to control the release profile of amantadine salt from the osmotic device;

d) the amantadine salt and osmotic salt have an ion in common;

e) amantadine salt is released through the one or more passageways according to a sigmoidal controlled release profile, optionally wherein release of amantadine salt is delayed for a period of time, when the osmotic device is exposed to an aqueous environment of use; and

f) the semipermeable membrane comprises a cellulose acetate grade 1 and a cellulose acetate grade 2, wherein the weight ratio of a cellulose acetate of high viscosity to the total amount of cellulose acetates ranges from 0:1 to 1:1, the cellulose acetates grade 1 has 7-10% by wt of hydroxyl groups, 30-36% by wt. of acetyl groups and a viscosity of 200-280 seconds, the cellulose acetate grade 2 has 3-5% by weight of hydroxyl groups, 37-43% by wt. of acetyl groups and a viscosity of 6.0-45.0 seconds, the unitary core comprises less than 6% of NaCl w/w based upon the weight of the uncoated core, and the semipermeable membrane comprises more than 25% w/w of cellulose acetate grade 1 based upon the weight of the semipermeable membrane.

2. The osmotic device of claim 1 further comprising an external coat comprising an active drug.

3. The osmotic device of claim 2 , wherein the active drug is an antidepressant.

4. The osmotic device of claim 3 , wherein the antidepressant is citalopram.

5. The osmotic device of claim 2 , wherein the active drug is an anxiolytic agent.

6. The osmotic device of claim 5 , wherein the anxiolytic agent is buspirone.

7. The osmotic device of claim 1 , further comprising a second active drug in the core.

8. The osmotic device of claim 7 , wherein the second active drug is an anti-Parkinson drug.

9. The osmotic device of claim 8 , wherein the second anti-Parkinson drug is selected from the group consisting of ropinirole, selegiline, and levodopa-carbidopa.

10. The osmotic device of claim 9 , wherein the second anti-Parkinson drug is ropinirole.

11. The osmotic device of claim 9 , wherein the second anti-Parkinson drug is selegiline.

12. The osmotic device of claim 9 , wherein the second anti-Parkinson drug is levodopa-carbidopa.

13. The osmotic device of claim 1 , wherein:

the amantadine hydrochloride is released according to a sigmoidal release profile from the core as follows:

Time (hours)

Amount Released

0-3

Not less than 5%

0-5

Not less than 18%

0-8

Not less than 39%

0-16

Not less than 76%.

14. The osmotic device of claim 13 , wherein the weight ratio of amantadine salt to osmotic salt ranges from 4:1 to 30:1, the semipermeable membrane comprises a weight ratio of cellulose acetate grade 1 to the total amount of cellulose acetates ranging from 0.3:1 to 0.7:1.

15. The osmotic device of claim 14 , wherein the bioavailability is greater than 87%, compared to the immediate release dosage form of the same dose.

16. The osmotic device of claim 13 comprising:

Ingredient

Amount (mg)

Core

Amantadine HCl

100

A First Diluent

 7-35

Binder

 3-10

Glidant

0.1-2  

Lubricant

0.3-3  

Sodium Chloride

3.33-50  

A Second Diluent

 3-20

First Coating

Cellulose acetate grade 1

 0-20

Cellulose acetated grade 2

 0-20

Plasticizer

0.2-1

17. The osmotic device of claim 13 comprising:

Ingredient

Amount (mg)

Core

Amantadine HCl

150

A First Diluent

10-55

Binder

4.5-15 

Glidant

0.2-3  

Lubricant

0.5-5  

Sodium Chloride

 5-75

A Second Diluent

4.5-30 

First Coating

Cellulose acetate grade 1

 0-25

Cellulose acetate grade 2

 0-25

Plasticizer

0.3-2

18. The osmotic device of claim 13 comprising:

Ingredient

Amount (mg)

Core

Amantadine HCl

300

A First Diluent

 20-100

Binder

10-30

Glidant

0.2-5  

Lubricant

1-7

Sodium Chloride

 10-150

A Second Diluent

10-60

First Coating

Cellulose acetate grade 1

 0-50

Cellulose acetate grade 2

 0-50

Plasticizer

0.5-3

19. The osmotic device of claim 1 , wherein the amantadine is released according to the following profile:

Performance

Performance

Time

Minimum

Maximum

(hrs)

(%)

(%)

1

0

4

3

16

27

5

35

59

8

55

83

12

77

100

16

84

100

24

86

100.

20. An osmotic device having a unitary core surrounded by a semipermeable membrane having at least one passageway there through, wherein:

a) the unitary core comprises a mixture of amantadine salt, osmotic salt, and at least one other pharmaceutically acceptable excipient;

b) the amantadine salt and osmotic salt have an ion in common;

c) the weight ratio of amantadine salt to osmotic salt is in the range of 30 : 1 to 2 : 1 ;

d) the semipermeable membrane comprises 1.7% -15.0% of a plasticizer, 33.3% -61.2% of cellulose acetate grade 1 and 33.3% -61.2% of cellulose acetate grade 2, wherein the cellulose acetates grade 1 has 7-10% by wt of hydroxyl groups, 30-36% by wt. or acetyl groups and a viscosity of 200-280 seconds, and the cellulose acetate grade 2 has 3-5% by weight of hydroxyl groups, 37-43% by wt. or acetyl groups and a viscosity of 6.0-45.0 seconds;

e) the unitary core comprises less than 6% of NaCl w/w based upon the weight of the uncoated core; and

f) amantadine salt is released through the one or more passageways according to a sigmoidal release profile when the osmotic device is exposed to an aqueous environment of use.

Assignments (3)
CHANGE OF ADDRESS FOR ASSIGNEE Recorded Jul 2, 2020
From: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KFT
To: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KFT
Reel/Frame 053122/0081 →
SECURITY INTEREST Recorded Feb 3, 2016
From: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KORLÁTOLT FELELOSSÉGU TÁRSASÁG
To: CIT BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 037656/0777 →
ASSIGNEE CHANGE OF ADDRESS Recorded Nov 20, 2013
From: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
To: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
Reel/Frame 031692/0741 →